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Abstract
Background: Policymakers and researchers seek answers to how liberalized drug policies affect people who inject
drugs (PWID). In response to concerns about the failing “war on drugs,” Mexico recently implemented drug policy
reforms that partially decriminalized possession of small amounts of drugs for personal use while promoting drug
treatment. Recognizing important epidemiologic, policy, and socioeconomic differences between the United
States—where possession of any psychoactive drugs without a prescription remains illegal—and Mexico—where
possession of small quantities for personal use was partially decriminalized, we sought to assess changes over time
in knowledge, attitudes, behaviors, and infectious disease profiles among PWID in the adjacent border cities of San
Diego, CA, USA, and Tijuana, Baja California, Mexico.
Methods: Based on extensive binational experience and collaboration, from 2012–2014 we initiated two parallel,
prospective, mixed methods studies: Proyecto El Cuete IV in Tijuana (n = 785) and the STAHR II Study in San Diego
(n= 575). Methods for sampling, recruitment, and data collection were designed to be compatible in both studies.
All participants completed quantitative behavioral and geographic assessments and serological testing (HIV in both
studies; hepatitis C virus and tuberculosis in STAHR II) at baseline and four semi-annual follow-up visits. Between
follow-up assessment visits, subsets of participants completed qualitative interviews to explore contextual factors
relating to study aims and other emergent phenomena. Planned analyses include descriptive and inferential
statistics for quantitative data, content analysis and other mixed-methods approaches for qualitative data, and
phylogenetic analysis of HIV-positive samples to understand cross-border transmission dynamics.
Results: Investigators and research staff shared preliminary findings across studies to provide feedback on
instruments and insights regarding local phenomena. As a result, recruitment and data collection procedures have
been implemented successfully, demonstrating the importance of binational collaboration in evaluating the impact
of structural-level drug policy reforms on the behaviors, health, and wellbeing of PWID across an international
border.
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Conclusions: Our prospective, mixed methods approach allows each study to be responsive to emerging
phenomena within local contexts while regular collaboration promotes sharing insights across studies. The
strengths and limitations of this approach may serve as a guide for other evaluations of harm reduction policies
internationally.
Keywords: Injection drug use, HIV, Hepatitis C virus, M. tuberculosis, Drug policy reform, Structural interventions,
Decriminalization, Mixed methods, International collaboration, Mexico
Background
Drug Policy Reform: decriminalization to reduce
drug-related health harms
Policymakers are increasingly acknowledging the harm-
ful consequences of drug prohibition [1]. Punitive drug
policies have largely failed to reduce the prevalence of
drug abuse [2], fuelled epidemics of HIV and hepatitis C
virus (HCV) infection [3-6], and discouraged the imple-
mentation and use of needle/syringe exchange programs,
opioid substitution treatment (e.g., methadone mainten-
ance), and other evidence-based public health interven-
tions [7,8]. Law enforcement and policing activities that
typically accompany drug control initiatives also result
in the criminalization and stigmatization of drug users
[9,10], high incarceration rates [11,12], human rights
abuses [13,14], and escalations in drug-related violence
and corruption leading to considerable political instabil-
ity [15]. Incarceration of drug users has also promoted
HIV and tuberculosis (TB) coinfection in many resource-
poor settings [10]. Amidst accumulating evidence that the
“war on drugs” has failed to curtail drug consumption and
trafficking while producing such unintended conse-
quences, experts have called for structural interventions
including drug policy reforms [16,17].
Liberalization of punitive drug policies represents one
alternative model to reducing the social and public health
harms associated with drug abuse [18]. In particular,
decriminalization of drug possession is gaining popu-
larity [19] and has been adopted by countries in Europe
(e.g., the Netherlands, Switzerland, and Portugal) [20] and
the Americas (e.g., Argentina, Bolivia, Brazil, Columbia,
Mexico, Peru, and Venezuela) [21-23]. Although no na-
tional drug policy reforms have been formally evalua-
ted to date, Portugal’s 2001 decriminalization is arguably
the best studied. Portugal’s reforms, which changed pos-
session from a criminal to administrative offense and
increased public health resources for drug abuse treat-
ment and prevention, have been considered successful
in reducing drug-related deaths, preventing transmis-
sion of HIV and HCV, and increasing utilization of
syringe exchange programs and drug treatment servi-
ces including methadone [24,25]. However, additional
research is needed in contexts outside of Portugal’sr e -
latively stable drug markets, functional police governance,
and availability of high quality, evidence-based drug treat-
ment services.
Reforms in Mexico
Recognizing the unintended consequences of punitive
drug policies including dramatic increases in violent
crime [16,17,19], Mexico recently enacted federal reforms
involving decriminalization and expansion of treatment
services [26]. This legislation, passed in 2010, decrimina-
lized possession of small, specified amounts of drugs for
personal use, including heroin (≤50 mg), cocaine (≤0.5 g),
methamphetamine (≤40 mg), and marijuana (≤5 g) [27].
The law specified that, in lieu of arrest, persons appre-
hended with lesser amounts of these drugs would be
released with only a police record until their third ap-
prehension, when they would be required to either enter
drug treatment or be incarcerated for 90 days. At the same
time, Mexico developed plans for national expansion of
drug treatment services. Legislation has been enacted by
states using varying strategies and timelines.
Proponents of Mexico’s reforms have argued that law
enforcement efforts will be appropriately redirected to-
ward curtailing drug trafficking, allowing public health
resources to be dedicated to new drug treatment services
for drug users [26]. However, opponents have raised con-
cerns about unintended consequences (e.g., increasing
drug availability, overdose, drug trafficking, or “drug tour-
ism” from countries with stricter drug laws) and because,
unlike Portugal, evidence-based drug treatment options
remain scarce in Mexico. Nevertheless, public funding to
expand drug treatment and methadone services is increas-
ing, suggesting the possibility of growing numbers of drug
users beginning drug treatment throughout Mexico over
the coming years.
Epidemiology of HIV, HCV, and TB in the U.S.-Mexico
Border Region
Understanding the impact of the recent reforms on
the health of drug users is of great interest to public
health officials in Mexico, where the HIV epidemic likely
stemmed from the U.S. epidemic. The first three cases of
HIV in Mexico were all identified in individuals who had
visited the United States [28]. The early epidemic was con-
centrated among men who had sex with men (MSM) [29].
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spread of HIV to other subgroups [30]. Although HIV
prevalence remains low in Mexico overall (overall pre-
valence was estimated at 0.3% in 2009), transmission
has been closely linked to drug abuse, particularly in
the Northern border region [31].
In cities such as Tijuana, Baja California, drug-related
HIV risk behaviors are of particular concern. “Spillover”
from heroin, cocaine and methamphetamine trafficking
routes destined for the United States has contributed to
increasing prevalence of drug abuse, especially injection
drug use [32,33]. Along the West coast of Mexico, the
lower purity “black tar” heroin remains more common
than the powder forms, causing heroin users in this region
to transition from smoking to injection more quickly [34].
In 2008, 4.8% of the population of Baja California reported
injecting drugs, compared to 0.2% in Mexico overall [35].
Baja California also had the highest prevalence of me-
thamphetamine abuse. Tijuana, where HIV has been asso-
ciated with drug abuse, arguably has the largest number of
people who inject drugs (PWID) per capita of any city in
Mexico [29].
Baja California has the second highest cumulative AIDS
incidence in Mexico (following the Federal District), com-
prising 4.7% of all AIDS cases in the country [31]. In 2006,
an estimated one in every 116 persons aged 15–49 years
in Tijuana was infected with HIV [36]. However, transmis-
sion, which has also been associated with active syphilis,
remains concentrated among high risk populations in-
cluding PWID (HIV prevalence of 4% overall; 3.5% among
men and 10.2% among women) [29] and female sex
workers ([FSWs]; HIV prevalence of 6%) [37]. Consistent
with studies worldwide showing that PWID are at height-
ened risk for HCV infection from sharing syringes and in-
jection paraphernalia, PWID in Tijuana have an extremely
high HCV prevalence at 95% [38,39]. TB incidence among
PWID in Tijuana is also high at 34 cases per 100 person-
years [40], suggesting prevalent untreated, active infection.
The majority of PWID (67%) and non-injecting drug users
(58%) in Tijuana have been shown to have latent TB infec-
tion (LTBI) [41], and their risk of progressing to active TB
increases from 10% over their lifetime to 10% annually if
they are coinfected with HIV [42].
Injection drug use in Tijuana, Mexico
We have been conducting epidemiologic and behavioral
surveillance among PWID in Northwestern Mexico’s
border region for a decade. Proyecto El Cuete (“cuete” is
slang for needle/syringe) represents a series of research
studies that has qualitatively and quantitatively described
injection behaviors [43,44], risk environments [45], and
drug treatment experiences among PWID in Tijuana
[46]. Although 95% of enrolled PWID reported injec-
ting heroin (alone or in combination with cocaine or
methamphetamine), more women than men used meth-
amphetamine (80% vs. 68%, p<0.01) [47], a concerning
finding due to the lack of effective treatment strategies for
methamphetamine abuse.
The El Cuete studies also helped link drug-related
harms among PWID to characteristics of the broader
social and policy environments. As in other settings
[6,48-51], police practices in Tijuana have exerted po-
werful influences on risk behaviors among PWID [44]. In
particular, findings revealed that unsanctioned arrests for
having “track marks” (evidence of injection) and confisca-
tion of syringes were commonly experienced by PWID
and were associated with higher prevalence of HIV in-
fection and associated injection-related risk behaviors
[52-54]. Specific behaviors associated with policing prac-
tices include higher frequency of injection [55], receptive
syringe sharing [56], seeking injection assistance from
others [57], and injecting in public places or shooting gal-
leries [52,56]. These findings underscore the importance
of law enforcement and the legal environment in which
blood borne infections are transmitted. However, the
extent to which Mexico’s drug policy reforms could posi-
tively influence policing practices while reducing incarce-
rations and improving injection contexts for PWID in
Tijuana remain unclear.
It is also unclear how quickly Baja California and other
states in Mexico with a heavy burden of drug abuse can
scale up evidence-based harm reduction services. While
syringe exchange programs are rare in Mexico, syringes
can be legally purchased without a prescription in phar-
macies, which is the only way for many PWID to ob-
tain sterile syringes. An observational study of PWID in
Tijuana found that 81% reported purchasing syringes at
pharmacies. However, within this subgroup, 16% repor-
ted being refused syringes or overcharged, which was as-
sociated with receptive syringe sharing, using syringes
multiple times (e.g., more than five uses per syringe),
and having greater numbers of abscesses [58]. In qualita-
tive interviews, PWID reported experiencing stigma and
other important social barriers to successfully purchas-
ing syringes at pharmacies, despite the fact that it is legal
for them to do so [59]. In other settings, PWID who
were unable to exchange or purchase syringes also re-
ported sharing used syringes [60] and obtaining syringes
from shooting galleries and other unsafe syringe sources
[49]. While Mexico’s reforms may promote syringe avail-
ability, the risk of facing a third apprehension for drug
possession while attempting to purchase syringes legally
could lead PWID to obtain syringes from more discreet
and higher risk sources.
Mexico’s reforms also call for a dramatic expansion of
drug treatment services. Among Tijuana PWID who re-
ported ever receiving help with drug cessation in a 2004–
2005 survey, most (80%) attended residential programs
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[46], despite the lack of evidence regarding the efficacy of
such programs in Mexico. In a qualitative subsample of
these PWID, nearly one quarter of those who had ever
attended residential treatment programs described being
physically or verbally mistreated by treatment center staff
[46]. Some even reported preferring incarceration to drug
treatment due to the negative reputations of rehabilitation
centers [46]. At the same time, the observed low uptake of
methadone maintenance in Tijuana has been attributed to
the high cost (approximately $10 /day), scarcity of ser-
vices, negative experiences with dosing, and perceptions
of ineffectiveness [61]. However, some U.S. residents have
reported preferring methadone treatment in Mexico [61].
While Mexico’s new drug policy includes funding that will
increase treatment availability and encourage drug users
to attend drug treatment rather than incarceration, the
quality and effectiveness of programs will require close
evaluation.
Injection drug use in San Diego, United States
The potential impact of Mexico’s policy reforms on the
health and wellbeing of drug users in the United States
also remains understudied. Tijuana and San Diego share
the world’s busiest land border crossing, and their com-
bined population of nearly six million residents is the
largest of all metropolitan regions along the 2000 mile-
long border [62]. The U.S.-Mexico border region is also
characterized by some of the most dramatic income dis-
parities between two adjacent countries in the world
[63]. Due to the dearth of published literature on PWID
in San Diego, despite recently published data from
Tijuana, epidemiologic and behavioral surveillance of
PWID in San Diego was started in 2009.
The “Study To Assess Hepatitis C Risk” (STAHR) was
a cross-sectional study of HIV and HCV infection among
PWID recruited in San Diego using street outreach, re-
spondent driven sampling (RDS), and venue based sam-
pling [64]. Although STAHR revealed that HIV prevalence
(4%) among PWID in San Diego was comparable to that
among PWID in Tijuana (4%) [53], it also pointed to vast
disparities between the two cities in the prevalence of
HCV and TB. As noted above, nearly all PWID in Tijuana
(95%) are HCV-positive [38,39], while PWID in San Diego
were found to have comparatively low HCV prevalence
(27%) [64]. Similarly, in contrast to the high prevalence of
LTBI among PWID in Tijuana [65], less than 15% of HIV-
positive PWID tested in a San Diego HIV clinic were
found to have LTBI [40,41]. The disparities in disease
prevalence between Tijuana and San Diego raised con-
cerns that PWID travelling from the United States to
Mexico to buy or use drugs could face increased risk of
acquiring these diseases through social, sexual, or drug
use interactions [64].
Cross-Border HIV Transmission: rationale for drug tourism
research
Research in other settings has documented how dual ep-
idemics of heroin injection and HIV follow drug traffick-
ing routes across international borders [66]. A study of
PWID in the China-Vietnam border region [67] iden-
tified a “gradient” of HIV prevalence that increased as
heroin originating in Southeast Asia moved north (i.e.,
from northern Vietnam to southern China) [68]. Studies
have also identified extensive international “drug tour-
ism” from countries with restrictive drug laws governing
the sale, possession, and use of drugs, to countries with
more liberal policies [69,70]. Many U.S. residents travel
to Mexico and Canada to obtain inexpensive prescrip-
tion medications [71-73]. PWID in San Diego have de-
scribed initially being influenced to travel to Mexico due
to the reputation of Tijuana as a party city with fewer re-
strictions on drinking [61]. For some, this early travel
evolved to include illicit drug use; however, data on the
prevalence of tourism for illicit drugs of abuse and the
associated risks remain sparse. In contrast to the situ-
ation in Mexico, possessing any amount of illicit drugs is
illegal in the United States. Due to lower perceived risk
of penalties following Mexico’s drug policy reforms,
these legal changes could create an atmosphere in which
drug users residing in the United States initiate or inten-
sify travel to Mexico to purchase or use drugs. Such
drug tourism by PWID from San Diego to Tijuana could
influence cross-border transmission of infectious dis-
eases. In particular, individuals taking part in this type of
tourism who acquire a blood borne infection could
“bridge” these diseases into geographically separated so-
cial networks.
Preliminary cross-sectional data from the STAHR stu-
dy indicated that two-thirds of participants had crossed
the border from San Diego into Tijuana, and more than
a quarter (27%) of this group had injected drugs in
Mexico [64]. Injecting in Mexico was associated with
injecting heroin, distributive syringe sharing at least half
of the time, and transporting drugs [74]. In qualitative
interviews, PWID who injected in Mexico reported gen-
erally heavier drug use and greater familiarity with the
border region [61]. Through qualitative interviews, they
described the drug market in Tijuana as more visible
and perceived that drugs were more readily available
in Tijuana. Travel to Tijuana served as an option for
some PWID to procure drugs when they were unable
to find them in San Diego. While PWID from Tijuana
were less likely to travel into San Diego due to U.S. cus-
toms restrictions, which generally require a passport, and
limited mobility (particularly due to U.S. deportation
records) [75], nearly half (48%) of PWID in Tijuana
reported ever injecting drugs with someone from the
United States [76].
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answered. First, while it was evident that a substantial
proportion of PWID in both countries had crossed the
border to use drugs, little was known about the social
context of this drug use. For example, it was unknown
whether PWID who travel from San Diego to Tijuana to
purchase and use drugs were injecting with fellow trav-
elers from San Diego or with PWID who reside in
Mexico. Second, given the rapidly changing nature of
policy reforms, including both Mexico’s policy reform
and changing U.S. border enforcement policies, we ex-
pected that patterns of, and motivations for, drug-related
border crossing would evolve over time. Given the exist-
ing patterns of drug tourism, it appeared possible that
Mexico’s reforms could inadvertently increase cross-
border travel for drug use, carrying with it multiple drug-
related adverse effects on health.
Based on the need to assess the effects of Mexico’s
drug policy reforms on drug abuse and related harms in
the U.S.-Mexico border region, we developed a bina-
tional research agenda involving two parallel studies: a
fourth phase of Proyecto El Cuete in Tijuana (i.e., El
Cuete IV) and a second phase of the STAHR study in
San Diego (i.e., STAHR II). Designed and implemented
in tandem, these two studies provide the opportunity to
evaluate the consequences of one country’s drug policies
on the behaviors and wellbeing of drug users in two
neighboring countries. The overall objective of El Cuete
IV, planned for 2010–2015 but extended through 2020,
is to assess the impact of Mexican drug policy reforms
on HIV-related risk and protective factors among PWID
in Tijuana, Mexico. Similarly, the objective of STAHR II,
planned for 2010–2015, is to assess the impact of Mexi-
co’s drug policy reforms on the knowledge, behaviors
and infectious disease status of PWID in San Diego, CA.
Specific aims of these projects include evaluating the ef-
fects of Mexico’s reform on knowledge, attitudes, risk
and protective behaviors, experiences with incarceration
and drug treatment, and prevalence and incidence of
overdose, HIV and other infections, and death among
PWID in Tijuana and San Diego.
Conceptual framework
To guide this binational research agenda, we developed
a multilevel framework with two primary conceptual
underpinnings. First, we drew from Rhodes’ Risk Envir-
onment Framework [10,77] to highlight the multilevel,
contextualized nature of HIV risks and better hypo-
thesize relationships between macro- and micro-level
factors. Rather than solely emphasizing individual-level
risk factors, this framework allowed us to emphasize
how macro-level structural changes (e.g., national drug
policy reforms) could influence health outcomes. Sec-
ond, we drew from the Diffusion of Innovations Theory
[78] to understand the processes by which information
about the new policies and associated attitudes spread
through social networks over time [79]. This framework
has been tailored to the unique research questions and
aims of each study and serves as a guide for our iterative
mixed-methods approach detailed in the next sections of
this paper.
Methods
Overview of binational mixed methods studies
El Cuete IV and STAHR II are prospective, mixed-
methods observational cohort studies that were designed
in parallel to allow triangulation of data from both cities.
Between 2012 and 2014, we recruited separate, non-
overlapping cohorts of PWID in each city to undergo
semi-annual behavioral and biological assessments. Based
on extensive binational collaboration and research ex-
perience with PWID in this region, U.S. and Mexican
investigators interacted regularly to develop and refine
complementary protocols and implement the two proto-
cols in tandem. El Cuete IV enrolled 785 PWID in Tijuana
to undergo behavioral assessments and HIV testing at
baseline and every six months for 24 months, while
STAHR II enrolled 575 PWID in San Diego to undergo
behavioral and biological assessments for HIV, HCV and
Mtb testing at baseline and every six months for 24
months. Although these studies were designed to be simi-
lar, we anticipated important differences in each context
and developed mixed methods designs that could be re-
sponsive to the needs of each study site. Thus, subsamples
of participants in both studies were selected after behav-
ioral assessment visits to complete qualitative interviews
to enhance our understanding of emergent phenomena
and the diverse contextual factors surrounding our re-
search aims. All procedures within both studies were ap-
proved by the Human Subjects Protections Program of
the University of California, San Diego.
Study populations
Sampling and recruitment
In both studies, sampling was driven by quantitative and
qualitative study aims. We restricted sampling to PWID
because they represented a group of drug users at ele-
vated risk for blood-borne infections and tend to be
more heavily affected by changes in the drug scene (e.g.,
new drug formulations that could change as a result
from the drug policy reforms). Rather than continuing
to follow El Cuete IV participants from the previous
phases of our binational research agenda, we decided to
recruit different individuals due to attrition, mortality,
and other temporal trends that affected our previous
cohorts.
We sought to obtain representative samples of PWID
in each site. Although we initially considered recruiting
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(RDS), due to issues of cost and the limited effectiveness
of RDS at recruiting female PWID [38,54], we instead
used targeted sampling consisting of street-based out-
reach in diverse geographic areas [80]. For example, El
Cuete IV outreach teams established temporary mobile
recruitment sites (e.g., vans and tents) in ten distinct co-
lonias (neighborhoods) characterized by different phy-
sical risk environments and where PWID were known
to spend time. Once situated in these neighborhoods,
outreach workers attempted to engage individuals in
conversation, sometimes by offering HIV prevention ma-
terials or information (e.g., condoms, educational pam-
phlets). Due to the drug related violence throughout
Mexico, we developed an approved safety protocol in
which outreach workers conducted all field-based re-
cruitment activities in pairs or teams rather than alone
and always carried identification cards to provide to po-
tential participants and authorities. While all outreach
workers in Tijuana spoke Spanish fluently, we also in-
cluded at least one English speaker in each outreach team
given the high numbers of U.S. deportees in our target
population.
STAHR II also used targeted sampling methods [80].
Recruitment involved direct street- and venue-based
outreach (e.g., outreach workers passed out recruitment
cards at parks, beaches, local syringe exchange vans and
other areas where PWID congregate); targeted adverti-
sing through local newspapers, websites (e.g., Facebook,
Craigslist), and posting flyers in neighborhoods and
venues with a high concentration of PWID; and social
networking strategies (e.g., peer referrals) within the target
population. In addition, the study developed a website
(http://www.ucsd-stahr.com) for potential participants to
access information about the study. All written materials
were available in English and Spanish. The outreach co-
ordinator also maintained close contact with health cen-
ters and community agencies serving PWID (e.g., local
syringe exchange programs). To better reach areas outside
of the downtown area where STAHR II maintained a pri-
mary study office, a mobile outreach van and temporary
office spaces were used to recruit PWID in northern, east-
ern, and southern San Diego County communities. These
mobile sites were equipped to conduct all of the screening
and data collection procedures described below. The
STAHR II outreach staff also worked in pairs or teams, re-
ceived study related trainings, and followed specific safety
precautions described in an approved injury and illness
prevention plan.
Eligibility criteria
In both studies, eligibility criteria included the following
characteristics: 1) being at least 18 years of age, 2) ha-
ving evidence of injecting illicit drugs within the past
month (i.e., confirmed by observation of track marks or
other physical evidence of injecting), 3) being able to
converse in English or Spanish, 4) currently residing in
the study city with no plans to move away within 24
months from enrollment date, and 5) not currently par-
ticipating in any intervention studies (although none to
our knowledge were being conducted). Individuals with
severe cognitive deficiencies or who were unwilling to
provide informed consent were excluded, and PWID who
met eligibility criteria but were too intoxicated to provide
informed consent were rescheduled for rescreening at a
later date.
Screening
Eligibility screening for both studies was conducted in
private rooms in primary study offices (both located in
commercial buildings) or at alternate sites (e.g., an off-
site clinic, mobile van, or tent set up in outside venues).
Screening began with the provision of general informa-
tion about the study aims and procedures. Potential par-
ticipants were asked for verbal consent before beginning
the screening interview. Screening instruments were
interviewer-administered, lasted approximately five mi-
nutes, and included several extraneous questions designed
to prevent potential subjects from guessing eligibility cri-
teria. Individuals were reimbursed $5 USD for their time
to complete the screening, regardless of eligibility. Ineli-
gible individuals were also offered free condoms, informa-
tion and referrals for HIV testing, and reimbursement for
public transportation as appropriate.
Informed consent
Following screening procedures, eligible PWID were
asked to provide written informed consent. Interviewers
handed potential subjects a copy of the consent form, read
through the consent document to highlight key content,
and discussed the study risks and benefits with the subject
to determine understanding of the procedures and answer
any questions that subjects had. In both sites, these mate-
rials were available in English and Spanish. Eligible indi-
viduals who decided to participate were asked to sign the
consent form and were then invited to immediately begin
baseline data collection unless they preferred to be res-
cheduled for a later time, which could require another eli-
gibility screening process to ensure that time-dependent
criteria were still met.
Qualitative subsamples
Subsamples of participants in each study were invited to
undergo in-depth interviews to obtain qualitative data.
Participants were purposively sampled on certain charac-
teristics (captured in quantitative described below) to ex-
plore knowledge and behaviors in the context of Mexico’s
legal reforms. Approximate sample sizes were determined
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which occurs when conducting additional interviews fails
to provide major new findings [82]. Due to the complexity
of themes that we intended to explore, and the possi-
bility of interviewing new participants and considering
additional emergent themes during subsequent waves
of qualitative data collection, we decided to initially con-
duct qualitative interviews with approximately 20 PWID
per wave. During qualitative data collection, investigators
held regular meetings in which interviewers presented
summaries of new and recurring findings so that the
research team could together evaluate saturation. Our
mixed methods designs were sufficiently flexible to allow
conducting qualitative interviews with additional parti-
cipants when new themes were identified and required
more in-depth exploration. Since the qualitative samples
were fully embedded within the longitudinal cohorts, con-
tacting additional participants was facilitated by a robust
tracking system designed for retention of participants over
multiple visits, as described below.
Retention and follow-up considerations
We developed active and passive follow-up strategies
based on our binational team’s successful experience fol-
lowing PWID and other marginalized populations. Dur-
ing enrollment for both studies, staff members collected
locator data on separate forms to facilitate participant
follow-up. For example, locator forms collected informa-
tion on where participants lived and spent time, their
direct contact information (if available), individual phy-
sical characteristics, and family/social contacts of partici-
pants. Mailing addresses were unavailable for many of
our participants, so one tracking strategy utilized in El
Cuete IV involved asking participants to locate on maps
where they lived (e.g., vacant lots, parks, canyons, shel-
ters) and spent time during different hours of the day
(e.g., panhandling spots, bars, clubs, food establishments).
Participants also received small, wallet-sized appointment
cards at enrollment that contained reminders of study
visits, incentive schedules, locations and contact informa-
tion for the study offices.
From our past cohort studies, we anticipated that re-
peated contact with participants would improve retention,
so El Cuete IV and STAHR II compensated participants
with $5 USD for brief “check-ins” at intervals halfway
between semi-annual assessment visits (e.g., at months 3,
9, 15, etc.). Outreach workers conducted check-ins in per-
son or by telephone, which involved asking participants to
update their locator information and reminding them
about future study appointments. All locator data were
maintained in a password protected locator database
stored separately from interview data to ensure confidenti-
ality. Each month, data managers provided staff with cal-
endars and lists of participants who were due for primary
and locator visits. Both studies developed logos that were
used throughout all methods of recruitment and tracking
to enhance participants’ recognition and recollection of
the study.
Staff also engaged in office- and street-based tracking
of participants. Office-based tracking involved phone,
text, email, postcard, and birthday card reminders, as
well as phone calls to family/social contacts listed on lo-
cator forms. After three unsuccessful contact attempts,
outreach workers proceeded to conduct home visits and
other forms of street-based tracking (e.g., visiting loca-
tions where participants indicated that they spent time).
Outreach staff also posted general notices describing the
study in English and Spanish at shelters, bus terminals,
airports, syringe exchange sites, health clinics, and drug
treatment programs on both sides of the border. Due to
the high numbers of migrants deported from the United
States to Tijuana each year, STAHR II utilized adminis-
trative data to help locate participants who were incar-
cerated in or deported to Mexico. At the same time, El
Cuete IV periodically searched for participants in neigh-
borhoods where they were recruited, homeless day cen-
ters (i.e., desayunadores), and prisons and drug treatment
centers.
Other retention strategies were specific to the contexts
of each site. Based on our research experience with mo-
bile PWID in San Diego, many of whom were unstably
housed, STAHR II also utilized escalating monetary re-
imbursements and small gifts (e.g., toiletries, condoms,
ID holders) to promote retention. For example, STAHR
II reimbursed participants $25 for completing baseline
surveys and testing, $25 at their 6-month visit, $30 at
their 12- and 18-month visits, and $50 for their final,
24-month visit. In between these data collection visits,
participants could also receive $10 for returning to re-
ceive their biological test results three weeks after each
assessment visit, and additional $5 payments for com-
pleting the locator visits described above. Participants
were informed that the total reimbursement amount
they could receive over the two-year course of the study
was $235. STAHR II also maintained the study website
(http://www.ucsd-stahr.com) and accounts on popular
social networking sites (e.g., Facebook) to keep in touch
with participants. Finally, STAHR II gave participants
wallet-sized calendars with toll-free phone number ac-
cessible from the United States and Mexico. Despite the
unique contexts of the lives of PWID in both settings,
both studies (and the experienced staff members dedi-
cated to each project) were able to inform the other with
respect to retention and tracking strategies.
Data collection
Data collection strategies were intended to be similar
across both studies, but we also recognized how studying
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from study designs that were flexible and responsive to
local events and changes in risk environments over time.
Both studies collected quantitative (survey) data and bio-
logical samples from the overall cohorts at baseline and
semi-annual follow-up visits. Embedded subsamples of
PWID were also selected from the two cohorts based on
each study’s specific aims to complete qualitative inter-
views at multiple time points [83]. Careful monitoring of
all forms of data collection was inherent in our study de-
signs and allowed for quantitative and qualitative instru-
ments to be refined in-between study visits to capture
new, emergent phenomena.
Quantitative data collection
For both studies, quantitative instruments were adminis-
tered in English or Spanish by trained bilingual inter-
viewers in confidential settings. Assessment instruments
for both studies were developed jointly by the same team
of investigators with the intention of creating identical
measures whenever possible and to provide information
from one study to complement data from the other
study. For example, the El Cuete IV assessed experiences
engaging in drug use with U.S. PWID to provide context
for questions in the STAHR II assessment about inject-
ing behaviors while in Mexico. This collaboration in
measurement was intended to facilitate joint analyses in-
cluding data from both cohorts. Bilingual, bicultural stu-
dy staff members who were familiar with the unique
language of the border region translated instruments
from English into Spanish as necessary. The bilingual
project director then back-translated these instruments
into English to assess accuracy. Bilingual interviewers
administered surveys using computer-assisted participant
interview (CAPI) technology, which we have used for pre-
vious studies in Mexico and the United States.
Quantitative instruments at baseline assessed lifetime
and recent experiences and behaviors, while follow-up
surveys emphasized the time elapsed since the prior in-
terview (six months). Socio-demographics measures in-
cluded race/ethnicity, place of birth, education, language
proficiency, citizenship and immigration status, passport
ownership, marital status, living situation, binational tra-
vel, migration and deportation experiences. Measures
of knowledge and attitudes focused on Mexico’sr e -
cent drug law reform, the health risks of using/injecting
drugs following reforms, and, for STAHR II participants,
travelling to Mexico to use drugs. For example, due to re-
cent drug-related deaths in Mexico and shifts in metham-
phetamine production from California to Baja California
[32,33], knowledge and perceptions among PWID in San
Diego regarding drug manufacturing could influence their
perceptions about the risks and benefits of using drugs
in Mexico.
Drug use behaviors included lifetime and recent use of
specific drugs and routes of drug administration (e.g.,
sniffing, smoking, swallowing, injecting), including routes
that could increase TB exposure (e.g., sharing pipes and
“shot-gunning,” the exhalation of smoke directly into an-
other person’s mouth) [84,85]. We also assessed syringe
and drug acquisition and periodically added new items in
response to reports about emerging trends were worth
monitoring in high risk communities (e.g., synthetic
drugs such as “bath salts” [i.e., synthetic cathinones]).
Drug treatment measures included lifetime and recent
experiences with voluntary and court-mandated drug
treatment involving diverse modalities (e.g. methadone,
outpatient vs. residential drug treatment, self-help groups),
barriers to accessing treatment, and perceptions regarding
service quality/efficacy. Sexual risk behaviors for HIV
transmission included number and types of partners, ex-
changing sex for money or other material goods, condom
use, and drug use with sex partners. Other health mea-
sures included access to healthcare, history of prior diag-
nosis and treatment for active TB or LTBI and HCV,
treatment type and completion, and symptoms [86]. Loca-
tion data for key outcomes of interest (e.g., interactions
with police) were obtained by showing participants elec-
tronic maps on laptop computers and asking them to indi-
cate exactly where such events occurred.
Serologic counseling and testing
Both studies conducted serologic testing for HIV infec-
tion at each visit. Participants received pre- and post-test
counseling according to the Mexican Ministry of Health
(El Cuete IV only) and U.S. Centers for Disease Control
(CDC) guidelines (both studies). Serologic testing in-
volved blood specimens collected via fingerstick and ve-
nipuncture according to standard clinical practice by a
trained phlebotomists who were experienced in obtain-
ing blood from PWID with scarred veins. El Cuete IV
used Advance Quality rapid HIV tests (InTec Products,
Inc). Reactive rapid tests were repeated. Participants re-
ceiving a second reactive rapid test were considered po-
sitive and referred to nearby municipal health clinics for
free care under Mexico’s universal health system (e.g.,
Centro de Salud No. 1 or CAPASITS).
In STAHR II, HIV testing was performed using Uni-
Gold TM Recombigen
W HIV rapid test on whole blood
collected via finger stick. For reactive tests, confirmatory
testing was performed using the OraQuick ADVANCE
W
Rapid HIV-1/2 Antibody Test (OraSure Technologies,
Bethlehem, Pennsylvania, USA). For reactive, inconclu-
sive, or discordant test results, additional blood samples
were collected and sent for confirmatory testing at the
San Diego County Public Health Laboratory. In addition
to serologic testing, we collected whole blood specimens
for HIV nucleic acid analysis using DNAgard
W Blood
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contain a stabilizing agent allowing blood to be stored at
room temperature without sacrificing DNA integrity or
recovery. Plasma and serum samples were also collected
at each visit for storage for future studies.
STAHR II also tested for HCV and Mycobacterium
tuberculosis (Mtb) infection. HCV testing was conduc-
ted using the OraQuick
W HCV Rapid Antibody Test
(OraSure Technologies, Bethlehem, Pennsylvania, USA).
Given the accuracy of this test, no confirmatory HCV
testing was performed. Participants testing HCV-positive
were referred to their health care provider or assisted
in identifying a provider who assess liver function and
test for active versus resolve infection. Testing for Mtb
infection was performed using the QuantiFERON
W TB
Gold In-Tube assay ([QFT] Cellestis, Carnegie, Victoria,
Australia). QFT requires blood samples to be incubated
overnight followed by enzyme-linked immunosorbant
assay; thus, participants were invited to return to receive
these results. Participants testing positive for Mtb infec-
tion required evaluation to rule out active TB and po-
tentially receive treatment for LTBI. In these situations,
counselors assisted them in making appointments with
their own physicians or referred them to the San Diego
County TB Control Program. In both studies, partici-
pants were retested for infections at each visit until re-
ceiving a positive result, after which they were no longer
retested for that infection. Referrals and educational re-
sources were also provided for substance abuse treat-
ment, management of wounds and abscesses, liver care,
domestic violence, hunger, and housing.
Qualitative data collection
In both studies, qualitative interview guides contained
broad, open-ended questions addressing study aims could
be amended to more specifically address emergent find-
ings. Interview guides were intended to be unstructured
enough to allow interviewers to explore these emergent
issues throughout the interview. Interviewers were also
extensively trained in conducting interviews in a nonjudg-
mental, conversational manner and probing for additional
details relating to study aims. Qualitative interviews were
digitally recorded and transcribed for content analysis.
During and after each interview, interviewers wrote de-
tailed summary notes on new and important findings and
reflected on emergent themes across interviews to inform
preliminary analyses. These notes were later presented du-
ring regular team meetings so that the research team
could identify commonalities across interviews and dis-
cuss progress towards achieving conceptual saturation. In-
terviewers also used feedback forms that were specifically
designed for each study to record additional information
on interview quality, participant demeanor, nonverbal be-
havior or emotions, and their general thoughts following
the interview. Interview transcripts, interviewer notes,
and feedback forms were translated as necessary for bi-
weekly phone and in-person team meetings and prelimi-
nary analyses.
Other data collection
The El Cuete IV study obtained permission to access
administrative records from Mexican authorities at the
municipal and state levels on the following outcomes
of interest: 1) drug treatment programs (e.g., type of
treatment, date of entry and exit, voluntary vs. court-
mandated, methadone dose, etc.), 2) interactions with
law enforcement (e.g., dates and types of arrests, numbers
of strikes, released vs. referred to drug treatment, etc.), 3)
incarceration (e.g., nature of conviction, date of entry and
exit, etc.). We also searched public registries semiannually
to obtain death certificates (e.g., using the Mexican Regis-
tro Civil or SEMEFO). STAHR II also obtained access to
publically available incarceration and reviewed death re-
cords to determine the status of participants who were
lost to follow-up.
Data analysis
Overall data analysis procedures were intended to be simi-
lar across our two mixed methods studies while also per-
mitting flexibility given the different settings and unique
study aims.
Quantitative data analyses
For both studies, descriptive statistics provided sum-
mary measures to describe initial and changes in know-
ledge, attitudes, experiences and behaviors in relation to
Mexico’s reforms (e.g., means, standard deviations, me-
dians, interquartile ranges, proportions). Frequency tables,
bar charts, and line graphs helped visualize the data. Bi-
variable, mediation and multivariable regression analyses
assessed potential correlates of our dependent variables
and identified potential interactions [87]. Longitudinal
analyses (e.g., using generalized linear mixed models)
were planned for determining the extent to which know-
ledge, attitudes, experiences and practices changed over
time and in relation to the implementation of legal re-
forms. Geographic analyses of location-based data were
also planned to help identify “hotspots” of key events and
outcomes of interest.
Phylogenetic analyses
In addition to statistical analyses, whole blood specimens
from HIV infected individuals underwent HIV nucleic
acid analysis. Samples were processed to extract DNA
and then amplify and sequence the pol region of HIV.
These sequences were then compared to our existing re-
search database of ≥1,000 HIV sequences from across
the San Diego-Tijuana border region. Utilizing a network
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tween sampled sequences by calculating the genetic dis-
tance between each pair of sequences (TN93 distance).
We considered a linkage to be present when a pair of se-
quences was found to be <1.5% different, a conservative
threshold based on our previous work in this area [88].
Qualitative data analyses
Occurring in tandem with data collection, qualitative
analyses have followed a thematic approach [83], drawing
from our conceptual framework to explore the multi-
level, contextualized nature of HIV and drug-related
harms in this border setting [10,77] and the ways in
which knowledge and attitudes spread through social
networks to affect health outcomes [78]. Interviewers
and investigators attended regular meetings to discuss
preliminary findings, develop coding schemes collab-
oratively [89], and identify emergent concepts to ex-
plore in future waves of data collection and analysis
[90]. Supplemental analyses of emergent themes were
also planned.
Results & discussion
Through a detailed explanation of our methodological
approach, we demonstrated the feasibility of implement-
ing binational mixed methods studies that borrow from
the principles of a “natural experiment” to evaluate the
effects of a high level structural intervention (i.e., a na-
tional policy change) in two diverse but interdependent
contexts. Through the unique collaboration represen-
ted by El Cuete IV and STAHR II, which involved exten-
sive interaction between investigators and research staff
across an international border, we successfully recruited
two parallel cohorts of PWID in San Diego (United States)
and Tijuana (Mexico). We believe that our experiences
can help inform future research on the impact of drug
policy reform on the health and wellbeing of drug users in
other international settings.
Overall, our prospective, mixed methods study design
was both exploratory (i.e., qualitative data helped de-
velop and refine conceptual models for how drug policy
reform impacts the behaviors and experiences of PWID)
[91], and complementary (i.e., findings from different
study components led to different but complementary
contributions to our understanding of complex local
phenomena) [92,93]. The iterative process of using qua-
litative and quantitative data to inform the methods and
interpretations of results from each study component
[92,93] contributed toward a more comprehensive un-
derstanding of the binational effects of Mexico’s drug
policy reforms on the health and wellbeing of PWID.
Our integration of multiple methods of inquiry gener-
ated important new hypotheses, refined analysis plans,
and enhanced interpretations of preliminary findings.
While traditional epidemiologic survey could miss the
key aspects of local contexts, a small qualitative study
could not necessarily capture larger trends in drug abuse
behaviors across this international border. Utilizing mul-
tiple research methods allowed us to offset the weak-
nesses of each individual method and helped address
q u e s t i o n st h a tc o u l dn o th a v eb e e na n s w e r e dt h r o u g h
single methods alone.
We integrating different research methods in several
ways that have been recommended in the literature [94].
First, as our qualitative samples were embedded within
two larger cohorts, we were able to use quantitative da-
tasets to identify potential qualitative interviewees who
met our purposive sampling criteria [83]. For example,
we used quantitative data to identify STAHR II partici-
pants who lived in different geographic areas of San
Diego County to compare their experiences traveling to
and using drugs in Mexico. Second, quantitative data
also provided strata on which qualitative themes could
be compared. Third, while quantitative data allowed us
to describe behaviors, geographic hotspots and associ-
ated outcomes, our qualitative data provided more rich,
narrative context on the reasons, meanings, and proces-
ses underlying quantitative associations, leading to en-
hanced interpretations of quantitative results. Fourth,
emergent qualitative findings led to the development
of additional quantitative hypotheses. Finally, our utiliza-
tion of HIV sequence analysis and newer phylogenetic and
network based analytic tools enabled us build upon our
quantitative findings regarding prevalence and incidence
by providing objective evidence about cross-border popu-
lation mixing and the implications for HIV epidemics on
both sides of the border.
An essential feature of our research agenda was the
flexibility built into our approach, which allowed prelim-
inary findings from different study components to inform
other study components (e.g., preliminary qualitative find-
ings from STAHR II helped refine future waves of quanti-
tative survey data collection in STAHR II and El Cuete IV)
[91]. We believe that conducting a comprehensive evalua-
tions of high level structural interventions such as national
drug policy reforms demands a research design that can
be responsive to local phenomena that evolve over time.
By embedding a flexible, prospective qualitative com-
ponent within two larger cohort studies, we were able
to conduct real-time assessments of ongoing events
while also understanding evolution in the perceptions
of PWID living through those events.
In both studies, flexible sampling strategies have allowed
the following-up on emergent themes during subsequent
waves of data collection. For example, in El Cuete IV,
we initially sought to conduct qualitative interviews
with participants who had received varying numbers
of drug possession apprehensions. Upon learning that
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layed and few PWID in Tijuana had received any strikes
at baseline, we modified our qualitative sampling criteria
to include any participants who reported being stopped
with and without being arrested. Our ability to proactively
seek additional qualitative respondents meeting the new
criteria was heightened by our use of quantitative survey
data [83]. Flexibility has also afforded us the ability to
follow-up on preliminary quantitative findings using sub-
sequent rounds of “member checking” qualitative inter-
views that solicit participants’ feedback on findings and
investigators’ interpretations [95].
This type of flexible and iterative sampling is a hall-
mark of traditional qualitative designs [96] that is rarely
integrated into large epidemiologic cohort studies. We
argue that there are multiple benefits of having a highly
responsive qualitative component but also acknowledge
that it requires additional inputs from investigators and
staff [97]. In our case, to meet this challenge, we have
held regular meetings to discuss emergent findings, in-
form investigators and staff working on the other parallel
study, and revise quantitative instruments accordingly. In-
vestigators and analysts also communicate across sites
regularly to share and confirm preliminary findings across
studies and identify emergent topics that warrant add-
itional investigation. Although time-consuming, we agree
with others that this iterative, flexible, and collaborative
approach yields more inclusive and nuanced findings with
important program and policy implications [98,99].
A final strength of our research agenda is our ability
to train a diverse new generation of harm reduction re-
searchers and practitioners by leveraging support from
the National Institutes of Health and the Fogarty Inter-
national Center. Examples of funding that we have ob-
tained include career development grants (e.g., Mentored
Research Scientist Development Awards [K01 grants]), in-
stitutional research training grants (e.g., T32 for pre- and
postdoctoral trainees), and diversity-promoting fellow-
ships and supplements. To date, the El Cuete series has
trained over 50 graduate students, medical students, fel-
lows and junior faculty from institutions on both side of
the border including the two largest public univer-
sities in this region: the University of California, San
Diego (UCSD) and the Universidad Autónoma de Baja
California (in Tijuana). The STAHR series has utilized
similar funding opportunities to train 16 students from
the high school through postdoctoral levels, as well as
medical residents and junior faculty from UCSD and San
Diego State University. Eleven of these trainees belong to
racial/ethnic minority groups. While the primary objective
of our training agenda has been to provide interdisciplin-
ary research opportunities for students and new investiga-
tors, particularly those from underrepresented minority
groups in the sciences, including diverse perspectives and
expertise within our team has also enhanced the quality
and meaningfulness of our research.
In designing our binational protocol, we considered
several potential limitations. First, our studies depend
largely on highly sensitive, self-reported behaviors. How-
ever, there is an extensive literature finding drug users’
self-reported behaviors to be valid [100-102]. As an add-
itional strategy for guarding against underreporting of
risky behaviors, we consistently assure participants that
all data is confidential and that we do not report any
behaviors or identities to authorities. To provide U.S. par-
ticipants with greater assurance that their data will be kept
confidential, STAHR II obtained a Certificate of Confiden-
tiality. To the extent possible, we attempt to confirm some
behaviors and experiences using objective administrative
data (e.g., from drug treatment programs, police records,
and jail/prisons). We also provide staff members with ex-
tensive training to increase their familiarity with the drug
scene (e.g., local drug abuse trends, slang currently used
on the street), which we believe enhances the rapport that
they are able to develop with participants. We believe that
this training and the resulting ability of staff members to
interact comfortably with participants in a nonjudgmental
manner serves to improve the reliability of self-reported
behaviors.
Other important limitations of our research relate to
sampling. Due to our nonrandom sampling strategies,
our results cannot be interpreted as representative of the
entire populations of PWID in Tijuana or San Diego.
Our data also have limited generalizability with respect
to other populations of PWID internationally, especially
in regions with different policies and where heroin and
methamphetamine are not the major drugs of abuse.
Sample size constraints may limit our ability to identify
all hypothesized effects. However, to minimize attrition,
our outreach teams were extensively trained in office-
and street-based tracking and the use of multiple active
and passive follow-up techniques. As part of our bi-
national collaboration, we also share information about
successful strategies between studies. We believe that
our collaborative, mixed methods approach, combined
with the innovation and fortuitous timing of our bi-
national research, will offset many of these limitations.
Conclusions
The description of our two parallel study protocols dem-
onstrates the feasibility of implementing a binational re-
search agenda designed to assess the impact of high
level structural interventions on the health and well-
being of PWID in Mexico and the United States. Our
extensive collaboration, combined with our flexible,
prospective mixed methods approaches, allowed us to
address each study’s specific aims and document emer-
ging phenomena within these diverse local contexts. By
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quantitative methods, our research strategy provided a
more holistic and sophisticated understanding of the
phenomenon under study than could be achieved by a
single-method design. It is our hope that the description
of these methods will help inform other research on the
impact of drug policy reform on the harm reduction
agenda.
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